Core Insights - Conduit Pharmaceuticals has successfully repaid a $600,000 promissory note to Nirland Limited, fulfilling all obligations under the agreement [1] - Nirland has converted approximately $1.7 million of the Senior Secured Promissory Note into shares of Conduit's common stock, reducing the company's debt obligations [2] - The company aims to leverage its improved financial position to support strategic goals and enhance shareholder value [3] Financial Updates - The promissory note had an original principal amount of $600,000, with a 12% annual interest rate, and was due to mature on October 31, 2025 [1] - The Senior Note, initially $2.65 million, was entered into on August 6, 2024, and has been amended multiple times, also bearing a 12% annual interest rate [2] Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company focused on an efficient model for compound development, utilizing AI and cybernetics [4] - The company is led by experienced pharmaceutical executives and aims to build an integrated platform-driven approach, seeking exits through third-party license deals after successful clinical trials [4]

Core Insights - Conduit Pharmaceuticals has successfully completed all milestones in Phase I of its collaboration with Sarborg Limited and is transitioning to Phase II, which will focus on developing personalized software dashboards to enhance operational efficiency and decision-making [1][4] Phase I Summary - The primary focus of Phase I was to establish a strong foundation for the collaboration, identify key inputs for the algorithmic approach, and align Sarborg's services with Conduit's strategic goals [2] - The collaboration, initiated in December 2024, aims to revolutionize drug development by leveraging AI technologies to streamline drug repurposing, accelerate discovery, optimize solid-form identification, and enhance clinical trial monitoring [2] - Phase I included management teach-in sessions, validation of proprietary inputs critical for Sarborg's cybernetic models, and a comprehensive market analysis of cocrystal candidates [2] Portfolio Alignment - Conduit and Sarborg worked closely to align AI-driven processes with Conduit's portfolio needs, ensuring proprietary inputs were tailored to maximize the potential of key assets, including AZD1656, AZD5904, AZD5658, CDT1656, and the AZD1656 cocrystals [3] - An in-depth market analysis of cocrystal candidates provided actionable insights into the competitive landscape, patent positioning, and market opportunities [3] Phase II Focus - The transition to Phase II will focus on building the technological infrastructure necessary to support AI-driven drug development for Conduit's current and future product portfolio [4] - A key deliverable of Phase II will be the creation of personalized software dashboards, designed to provide real-time access to critical data related to clinical trials, drug discovery, and portfolio management [4] - These dashboards aim to enable more agile and informed decision-making, allowing the company to remain focused on delivering impactful clinical trials in autoimmune disorders [4] Company Overview - Conduit Pharmaceuticals is a dynamic, multi-asset clinical stage life science company that delivers an efficient model for compound development [5] - The company acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by AI and cybernetics, seeking exits through third-party license deals following successful clinical trials [5] - The leadership team includes experienced pharmaceutical executives, indicating a strong foundation for the company's innovative approach [5]

Core Insights - Conduit Pharmaceuticals is integrating advanced AI and cybernetics to enhance drug development processes, aiming to streamline operations and improve efficiency [1][3] - The company has completed initial milestones in collaboration with Sarborg Limited, focusing on AI-driven processes tailored to Conduit's portfolio [2][3] - Conduit aims to lead in the application of advanced technology in the pharmaceutical sector, promising faster and more cost-effective drug development [3] Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company that develops Phase 2-ready assets and employs an AI-driven approach to drug development [4] - The company is led by experienced pharmaceutical executives, including Dr. David Tapolczay and Dr. Freda Lewis-Hall, and seeks to exit through third-party licensing deals after successful clinical trials [4]

Core Viewpoint - Conduit Pharmaceuticals Inc. has announced a 1-for-100 reverse stock split to comply with Nasdaq's minimum bid price requirement and enhance the stock's marketability [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect on January 24, 2025, at 5:00 PM Eastern Time, with trading on a reverse-adjusted basis starting January 27, 2025 [2]. - Every 100 shares of common stock will be combined into one share, resulting in approximately 1.5 million outstanding shares post-split [3][4]. - The par value per share remains unchanged at $0.0001, and adjustments will be made to equity awards and convertible securities accordingly [3]. Group 2: Trading and Administrative Aspects - The common stock will continue to trade under the ticker symbol "CDT" with a new CUSIP number of 20678X205 after the reverse stock split [4]. - No fractional shares will be issued; stockholders entitled to fractional shares will receive a proportional cash payment [4]. - VStock Transfer, LLC will act as the exchange agent, and registered stockholders will not need to take action to receive post-split shares [5]. Group 3: Company Overview - Conduit Pharmaceuticals is a clinical stage, disease-agnostic life science company focused on efficient compound development, acquiring and funding Phase 2-ready assets [7]. - The company aims to exit through third-party license deals following successful clinical trials, differing from traditional pharma/biotech models [7].

Core Insights - Conduit Pharmaceuticals has entered into a strategic services agreement with Agility Life Sciences to develop new solid oral-dosage form products for its autoimmune pipeline, aimed at future clinical trials [1][2] Group 1: Company Overview - Conduit Pharmaceuticals is a multi-asset, clinical stage, disease-agnostic life science company focused on acquiring and funding Phase 2-ready assets, seeking exits through third-party licensing deals after successful clinical trials [5] - Agility Life Sciences is an award-winning formulation development CDMO that specializes in creating smart formulations to enhance the probability of success in pre-clinical studies [4] Group 2: Strategic Collaboration - The collaboration with Agility will leverage Conduit's proprietary solid forms, protected by newly established composition-of-matter intellectual property, to develop enhanced oral dosage forms tailored to patient preferences and disease-specific needs [2][3] - Conduit’s pipeline includes candidates with clinically tested oral formulations, allowing for efficient advancement into Phase 2 trials using existing data packages [3] Group 3: Market Positioning - The dual-track approach of developing enhanced proprietary oral dosage formulations while conducting ongoing clinical trials is intended to strengthen market protection, enhance market value, and optimize positioning for future licensing opportunities [3]

Core Insights - Conduit Pharmaceuticals has partnered with SARBORG Limited to utilize artificial intelligence and cybernetics for enhancing drug development processes, including drug repurposing, discovery, and clinical trial monitoring [1][2][3] Group 1: Partnership Details - The agreement with SARBORG aims to address challenges in the pharmaceutical sector by reducing human error in decision-making processes related to clinical development and asset identification [3][4] - Conduit will gain access to advanced predictive models and dashboards, which will facilitate the evaluation of drug candidates and streamline clinical trials [4][5] Group 2: Strategic Advantages - By integrating SARBORG's AI and cybernetics technology, Conduit aims to enhance efficiency, lower costs, and accelerate timelines in drug development [3][6] - The partnership is expected to provide Conduit with a strategic advantage, allowing for quicker and more accurate identification of opportunities in the market [7] Group 3: Long-term Vision - Conduit retains a perpetual, non-exclusive, royalty-free right to use any technology developed by SARBORG, ensuring ongoing support and innovation in areas such as intellectual property creation and regulatory strategy [5][6] - The collaboration reinforces Conduit's commitment to leveraging AI-driven solutions to maintain a competitive edge in the pharmaceutical industry [6]

Core Insights - Conduit Pharmaceuticals has received approval from the Japan Patent Office for a composition of matter patent for its lead asset, AZD1656, which targets autoimmune disorders [1][2] - This patent approval follows a similar grant in Australia, indicating the company's ongoing efforts to protect its intellectual property and enhance out-licensing opportunities [1][2] Company Overview - Conduit Pharmaceuticals operates with a unique business model aimed at addressing unmet medical needs by enhancing the intellectual property of its assets through advanced solid-form technology [3] - The company holds exclusive licenses with AstraZeneca for AZD1656, AZD5658, and AZD5904, and has additional cocrystal assets, including CDT1656, which expands its innovative portfolio [4] - The primary indications targeted by Conduit are Lupus and ANCA Vasculitis [4] Leadership - The company is led by a team of experienced pharmaceutical executives, including CEO Dr. David Tapolczay and Chair Dr. Freda Lewis-Hall, both of whom have significant backgrounds in the industry [5]

Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41245 CONDUIT PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | |------------- ...

Conduit Pharmaceuticals announces new addition to its autoimmune pipeline, underscored by composition of matter patent filing to strengthen its competitive position This new asset, CDT1656, combines AZD1656 with a second known-compound that has demonstrated immune-modulating effects across multiple autoimmune conditions, enhancing its therapeutic potentialThe addition of CDT1656 and the supporting composition of matter patent filing highlight Conduit’s commitment to building a robust asset portfolio, positi ...